18.3 Melanoma Histopathology, Breslow Thickness & Staging

18.3 Melanoma Histopathology, Breslow Thickness & Staging

Histopathologic Evaluation and Microstaging

The microscopic evaluation of cutaneous melanoma provides the essential parameters that dictate surgical margins, staging classification, sentinel lymph node biopsy eligibility, and adjuvant systemic therapies. Dermatopathological assessment must be conducted on completely excised, well-oriented specimens cut perpendicular to the skin surface.

1. Breslow Thickness

First described by Alexander Breslow in 1970, Breslow thickness remains the single most powerful, reproducible, and independent prognostic variable for localized primary cutaneous melanoma.

• Measurement Technique: Breslow thickness is measured perpendicularly using a calibrated ocular micrometer on hematoxylin and eosin (H&E) stained sections. Measurement begins at the top of the epidermal granular cell layer (stratum granulosum)—or if the surface is ulcerated, from the base of the necrotic ulcer bed—and extends to the deepest invasive viable melanoma cell within the dermis or subcutaneous fat.
• Reporting Standard: Recorded in millimetres to the nearest 0.1 mm (e.g., 0.8 mm, 1.4 mm, 3.2 mm).
• Exclusion Rules: Melanocytes migrating down hair follicles or sweat ducts are excluded from depth measurement unless they have breached the adnexal basement membrane and invaded the surrounding reticular dermis.
• Clark Levels vs. Breslow Depth: Historical Clark levels (Levels I–V based on anatomical layer of penetration) have been completely superseded by Breslow depth in formal AJCC staging. Clark level is subjective, vulnerable to anatomical variations in dermal thickness (e.g., eyelid vs. back), and provides no independent prognostic value when Breslow depth and ulceration are accounted for.

Stratum Corneum  =======================================================
Stratum Granulosum [ TOP OF MEASUREMENT ] ──┐
Stratum Spinosum                           │
Basal Layer       ~~~~~~~~~~~~~~~~~~~~~~~~~│~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ (Basement Membrane)
Papillary Dermis                           │  BRESLOW THICKNESS (mm)
                                           │  (Measured perpendicularly
                                           │   via ocular micrometer)
Reticular Dermis                           │
                  [ DEEPEST INVASIVE TUMOUR CELL ] ──┘
Subcutaneous Fat  -------------------------------------------------------

2. Histopathological Ulceration

Ulceration is the second most critical primary microstaging variable in cutaneous melanoma.

• Histological Definition: A full-thickness defect of the epidermis (complete loss of stratum corneum, granulosum, and spinosum down through the basement membrane), associated with an overlying fibrinous-necrotic exudate containing neutrophils, and evidence of an active host reactive response (granulation tissue or capillary proliferation) in the immediately adjacent underlying dermis.
• Artifact vs True Ulceration: Traumatic epidermal denudation, mechanical excoriation, or shaving artifact lacking fibrin deposition and dermal inflammatory reaction must not be recorded as true ulceration.
• Biological & Staging Impact: Ulceration indicates aggressive biological behavior, rapid tumor proliferation outstripping local vascular supply, and impaired immune surveillance. Across every single Breslow thickness stratum, the presence of ulceration substantially lowers melanoma-specific survival. In the AJCC 8th edition staging system, ulceration serves as an obligatory dichotomous factor dividing each T category into 'a' (non-ulcerated) and 'b' (ulcerated).

3. Mitotic Rate

• Evaluation Protocol: Evaluated across the entire invasive dermal component using the "hot spot" technique. The pathologist identifies the dermal field containing the highest concentration of mitotic figures and counts all distinct mitoses over a surface area of 1 square millimetre (mitoses/mm²) using contiguous high-power fields.
• AJCC Staging Evolution: In the AJCC 7th edition, a mitotic rate ≥1/mm² was a primary staging criterion that converted T1a lesions into T1b. In the AJCC 8th edition, mitotic rate was removed from the formal T1 staging definition following the introduction of the 0.8 mm Breslow cutoff. However, mitotic rate remains a mandatory prognostic reporting parameter in all European dermatopathology guidelines because it correlates continuously and linearly with recurrence risk, sentinel node positivity, and disease-free survival.

4. Additional Essential Microstaging Criteria

• Lymphovascular Invasion (LVI): Presence of melanoma cells within endothelium-lined lymphatic spaces or blood vessels. Strong independent predictor of regional lymph node metastasis and distant systemic dissemination.
• Perineural Invasion (PNI): Invasion into the perineural space or wrapping of melanoma cells around dermal nerve twigs. Highly prevalent in desmoplastic melanoma; strongly associated with local recurrence and failure to achieve clear histological margins.
• Microscopic Satellitosis: Any focus of metastatic tumour cells in the skin or subcutis adjacent or deep to the primary melanoma, completely discontinuous from it. The AJCC 8th edition removed the older size and distance criteria. In the AJCC 8th edition, microscopic satellitosis is staged as N1c (or N2c/N3c depending on nodal status), automatically elevating the patient to Stage III disease regardless of primary Breslow thickness.
• Tumour-Infiltrating Lymphocytes (TILs): Categorized according to the Clark classification:
  • Brisk: Lymphocytes diffusely infiltrating throughout the entire dermal invasive tumor base or across all tumor nests.
  • Non-brisk: Focal or patchy lymphocytic infiltration confined to isolated zones.
  • Absent: No lymphocytes present within the tumor, or lymphocytes restricted to peritumoral fibrous tissue without contacting tumor cells.
  • Prognostic Significance: Brisk TILs reflect an effective host anti-tumor cellular immune response and are associated with a significantly reduced risk of sentinel lymph node metastasis and improved overall survival.
• Melanoma Regression: Characterized histologically by the loss of melanoma cells replaced by dense dermal fibrosis, ectatic telangiectatic capillaries, and abundant melanophages accompanied by variable lymphocytic infiltrate. Complete regression can result in "metastatic melanoma of unknown primary". Extensive regression (>75% of tumor volume) historically raised concern for underestimating true initial Breslow thickness.

---

Definitive Surgical Wide Local Excision (WLE) Margins

Following complete excisional biopsy and histopathological verification of melanoma, the patient must undergo a definitive wide local excision (WLE) around the primary biopsy scar. The objective of WLE is to eradicate local subclinical micrometastases and prevent local recurrence.

European Surgical Margins (EADO 2022 Guideline)

Depth of Excision and the Deep Fascia

• Standard Depth: The excision must be carried out through the full thickness of the skin and subcutaneous fat down to, but not including, the deep investing muscular fascia.
• Preservation of Deep Muscular Fascia: Large randomized trials have demonstrated that routine excision of the deep muscular fascia does not improve local recurrence rates or overall survival. Preserving the intact glistening muscular fascia maintains an anatomic barrier against deep tumor seeding, minimizes severe cosmetic defects, and preserves regional lymphatic drainage channels critical for lymphatic mapping.

The Historical 3-to-5-cm Margins: Why Wider Is Not Better

Historically, surgeons performed radical excisions with 3 to 5 cm margins, often requiring extensive autologous skin grafting or local rotational flaps. Landmark randomized prospective trials (Intergroup Melanoma Trial, UK Melanoma Study Group, French Cooperative Group, and Swedish Melanoma Trial) conclusively demonstrated that:

1. Excising margins wider than 2.0 cm provides zero survival benefit and does not reduce regional recurrence.
2. Radical wide margins cause substantially higher rates of chronic pain, graft contracture, wound infection, prolonged hospitalization, and functional impairment.

---

Sentinel Lymph Node Biopsy (SLNB)

Regional lymph node status is the single most critical prognostic determinant for survival in patients with clinical Stage I and II cutaneous melanoma. Because lymphatic drainage from the skin is often unpredictable—particularly on the trunk, head, and neck where drainage may cross anatomical midlines—lymphatic mapping via sentinel lymph node biopsy is the standard of care.

Dual Mapping Technique (Gold Standard Protocol)

European practice uses preoperative radiocolloid lymphoscintigraphy, often combined with an optical tracer:

1. Preoperative Dynamic Lymphoscintigraphy (Radiocolloid):
   • Intradermal injection of technetium-99m (99mTc) labeled nanocolloid of human serum albumin or sulfur colloid around the intact excisional biopsy scar.
   • Dynamic planar gamma camera imaging and single-photon emission computed tomography combined with conventional CT (SPECT-CT) are performed 1 to 3 hours prior to surgery. This identifies the exact anatomical nodal basin(s), the number of sentinel nodes, and flags aberrant or in-transit drainage channels.
2. Intraoperative Optical Mapping:
   • Intradermal injection of 1 to 2 mL of patent blue V dye (or indocyanine green [ICG] for near-infrared fluorescence) around the scar 10 to 15 minutes before surgical incision.
   • In the operating theater, the surgeon uses a handheld gamma probe to identify the cutaneous hot spot. A small targeted incision is made over the basin, and nodes that are radioactive ("hot", defined as counts >10% of the hottest node ex vivo) and/or stained with blue dye ("blue") are meticulously excised.

Primary Biopsy Scar (e.g., Trunk)
   │
   ├── Intradermal 99mTc Radiocolloid (Preoperative SPECT-CT Lymphoscintigraphy)
   └── Intradermal Patent Blue / ICG (Intraoperative Optical Visualisation)
   │
   ▼
Afferent Lymphatic Vessel Migration
   │
   ▼
SENTINEL LYMPH NODE (First draining nodal station)
   ├── Radioactive ("Hot" via handheld gamma probe >10% threshold)
   └── Stained ("Blue" or fluorescent via near-infrared ICG)
   │
   ▼
Targeted Surgical Excision of SLN (Low morbidity)
   │
   ▼
Histopathological Evaluation (Serial Sectioning + S100/SOX10/Melan-A IHC)
   ├── Negative SLN (>99% certainty of downstream node negativity; excellent prognosis)
   └── Positive SLN (Micrometastasis detected; staged as Stage III, eligible for systemic therapy)

Clinical Indications for SLNB (European Consensus)

• Mandatory Discussion and Recommendation:
  • All patients with primary melanoma with Breslow thickness >1.0 mm (pT2a and above).
  • Primary melanomas classified as pT1b: Breslow 0.8 to 1.0 mm (regardless of ulceration).
  • Primary melanomas classified as pT1b: Breslow <0.8 mm WITH ulceration.
• Not Recommended:
  • Patients with pT1a melanoma (Breslow <0.8 mm, non-ulcerated), because the baseline likelihood of a positive sentinel node is <5%. The procedural risks (infection, seroma, wound dehiscence) outweigh the diagnostic staging benefit.
  • Patients with clinically palpable or radiologically confirmed macroscopic nodal metastasis (Stage III) or distant metastasis (Stage IV); these patients undergo therapeutic node dissection or systemic therapy directly.

The Paradigm Shift: MSLT-I and MSLT-II Trials

1. MSLT-I (Multicenter Selective Lymphadenectomy Trial I):
   • Demonstrated that SLNB accurately identifies nodal micrometastases and that in patients with nodal disease, immediate completion lymphadenectomy at the time of positive SLNB provided superior 10-year disease-free survival compared to observation until nodal recurrence became palpable.
2. MSLT-II (Multicenter Selective Lymphadenectomy Trial II) & DeCOG-SLT:
   • Evaluated whether patients with a tumor-positive SLNB benefit from immediate completion lymph node dissection (CLND) compared to active high-resolution ultrasound nodal surveillance.
   • Definitive Findings: Immediate CLND provided no melanoma-specific survival (MSS) benefit and no overall survival (OS) benefit compared to ultrasound surveillance. However, CLND caused severe, irreversible morbidity: chronic debilitating lymphedema occurred in 24% of the CLND arm versus only 6% in the surveillance arm, accompanied by elevated wound infection and nerve injury rates.
   • Current European Standard: Routine completion lymphadenectomy (CLND) is completely abandoned for SLNB-positive melanoma. Instead, patients with a positive SLN are managed with:
     1. Serial high-resolution nodal ultrasound every 3 to 4 months for the first 2 to 3 years, then every 6 months up to year 5.
     2. Multidisciplinary referral for adjuvant systemic therapy (anti-PD-1 immunotherapy or targeted BRAF/MEK inhibitors).

---

AJCC 8th Edition Staging System

The American Joint Committee on Cancer (AJCC) 8th edition staging system for cutaneous melanoma incorporates primary tumor (T), regional node (N), and distant metastasis (M) criteria.

1. Primary Tumour (T) Staging

2. Regional Lymph Node (N) Staging

The 8th edition stratifies N categories based on the number of involved regional nodes, whether nodal disease is clinically occult (detected by SLNB, subcategory 'a') or clinically apparent (palpable or radiologically visible macrometastasis, subcategory 'b'), and the presence of in-transit, satellite, or microsatellite metastases (subcategory 'c'):

3. Distant Metastasis (M) Staging and the LDH Modifier

The AJCC 8th edition distant metastasis classification categorizes anatomical metastatic sites in hierarchical prognostic order and integrates serum lactate dehydrogenase (LDH):

• M1a: Distant metastasis to skin, subcutaneous tissue, muscle, or distant (non-regional) lymph nodes.
• M1b: Distant metastasis to the lungs (with or without M1a involvement).
• M1c: Distant metastasis to other non-CNS visceral sites (liver, gastrointestinal tract, spleen, bone, adrenal glands), with or without M1a/M1b involvement.
• M1d: Distant metastasis to the Central Nervous System (CNS)—including brain parenchyma, cranial nerves, leptomeninges, and spinal cord—with or without other systemic metastases.
• The Serum LDH Modifier: In the 8th edition, elevated serum LDH is no longer restricted to defining M1c; instead, LDH is applied across every M category using bracketed suffixes:
  • (0): Normal serum LDH (e.g., M1a[0], M1b[0], M1c[0], M1d[0]).
  • (1): Elevated serum LDH (e.g., M1a[1], M1b[1], M1c[1], M1d[1]).
  • Elevated serum LDH reflects high total tumor volume, extensive glycolytic metabolism, and systemic tumor burden, and confers a significantly worse median overall survival across all metastatic anatomical sites.